MCM4

Across TCGA pan-cancer cohorts, MCM4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MCM4 data layer compared with 28 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MCM4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MCM4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, LUAD, and BLCA are the cancer types where MCM4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.053	0.936	<.001	12	view →
LUAD	OS	Median	All	0.328	0.702	.006	8	view →
BLCA	OS	Median	III,IV	0.236	0.583	.018	6	view →
UCEC	DFS	Median	All	0.919	0.622	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MCM4–DLBC (OS)

Open the DLBC breakdown →